Diagnosis and treatment status of primary immune thrombocytopenia
10.3760/cma.j.cn121090-20241104-00431
- VernacularTitle:原发免疫性血小板减少症诊疗现状
- Author:
Qiuzhe WEI
1
;
Qinying XIE
;
Linlin HUANG
;
Guolin YUAN
;
Huili CAI
;
Daozi JIANG
;
Yuanyan TANG
;
Shimin CHEN
;
Hongbo RENG
;
Heng MEI
Author Information
1. 华中科技大学同济医学院附属协和医院血液科，武汉 430022
- Publication Type:Journal Article
- Keywords:
Thrombocytopenia;
Retrospective analysis;
Quality of life
- From:
Chinese Journal of Hematology
2025;46(6):530-536
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To review the diagnosis, treatment and quality of life of patients with primary immune thrombocytopenia (ITP) in seven medical centers in some areas of Hubei Province.Methods:A retrospective analysis was conducted on age, disease course, symptoms, diagnosis, and treatment status (including testing items, drug selection, and adverse reactions) of patients with ITP in seven medical centers in Hubei Province from January 2020 to December 2022. An online survey was conducted on the quality of life of patients using the ITP Patient Assessment Questionnaire (ITP-PAQ) .Results:Among the 1033 patients, those with newly diagnosed, persistent, and chronic ITP accounted for 39.8%, 19.1%, and 41.1%, respectively. Most patients exhibit varying degrees of bleeding. Regarding treatment, corticosteroids and thrombopoietin drugs are the most commonly chosen treatment drugs for ITP, and the adverse reactions to treatment mainly include diarrhea, liver dysfunction, and thrombosis. The ITP-PAQ survey of 125 patients revealed that ITP significantly impairs their life quality. Patients with ITP scored significantly lower in fatigue, sleep, fear, exercise, work, and social aspects.Conclusion:A relatively high proportion of patients with ITP progressed to the chronic phase. Corticosteroids and thrombopoietin drugs are the two main treatment drugs for ITP patients. The quality of life of patients with ITP is significantly reduced in multiple dimensions.
